3,4-dimethoxy-1,2,5-thiadiazole-1-oxide 、 7-(dimethylamino)hept-5-ynylamine 以to give a solution of 3-methoxy-4-[7-dimethylaminohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide的产率得到3-methoxy-4-[7-dimethylaminohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide
Compounds of the formula (I)
or pharmaceutically acceptable salts are described, wherein R1 and R2 are independently hydrogen or C1-6alkyl, or R' and R2 together represent -(CH2)q- wherein q is 4 to 7, to torm together with the nitrogen atom to which they are attached, a 5-8 membered saturated ring, optionally substituted by C1-6alkyl; X is -CH2- or sulphur; n is 2 or 3, or if X is -CH,- n can also be 1; p is 1 or 2; and R' is hydrogen, C1-6alkyl, C3-6 alkenyl or C3-6alkynyl (wherein the unsaturated bond is not adjacent to the -NH- moiety).
The compounds are histamine H2-receptor antagonists and are useful in treating diseases mediated via histamine H2-receptors. Processes for their preparation, pharmaceutical compositions containing them and methods of use are described.
This invention relates to Mannich-alkynyl aminothiadiazole oxides having histamine H.sub.2 -antagonist activity. A particular compound of this invention is 3-amino-4-[7-piperidinohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide.
Intermediates for 3-amino-1,2,5-thiadiazole-1-oxides
申请人:Smith Kline & French Laboratories Limited
公开号:US04732980A1
公开(公告)日:1988-03-22
This invention relates to intermediates of Mannich-alkynyl aminothiadiazole oxides having histamine H.sub.2 -antagonist activity. A particular final product of this invention is 3-amino-4-[7-piperidinohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide.